Alto Neuroscience (ANRO) Cash from Financing Activities (2023 - 2026)

Alto Neuroscience has disclosed Cash from Financing Activities across 4 years of filings, most recently posting $114.9 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $114.9 million, up 1159.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $165.9 million (up 1517.04% YoY), and the FY2025 annual result was $60.1 million, down 55.72% from the prior year.
• Cash from Financing Activities came in at $114.9 million for Q1 2026 at Alto Neuroscience, up from $50.2 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $134.6 million in Q1 2024 to a low of -$234000.0 in Q2 2024.
• The 4-year median for Cash from Financing Activities is $1.3 million (2024), against an average of $29.1 million.
• Across the five-year window, Cash from Financing Activities sank 358.82% in 2024 and jumped 102318.37% in 2025, its largest moves.
• Alto Neuroscience's Cash from Financing Activities stood at $43.1 million in 2023, then tumbled by 99.89% to $49000.0 in 2024, then surged by 102318.37% to $50.2 million in 2025, then surged by 129.03% to $114.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $114.9 million (Q1 2026), $50.2 million (Q4 2025), and $153000.0 (Q3 2025), per Business Quant data.